Shots:

• The two P-III studies (COUGH-1 &-2) involves assessing of gefapixant (45mg- 15mg- bid) vs PBO in 732 & 1-317 patients with refractory or unexplained chronic cough with 1EP as 24hrs. cough/hr. @12wks. and 24wks. respectively
• Gefapixant (45mg- bid) arm met its 1EPs i.e- decrease in 24hrs. coughs/hr. @12wks. & 24wks. while gefapixant (15mg- bid) arm did not meet its 1EP- safety & tolerability of gefapixant is consistent with the previous studies
• Gefapixant (PO) is an investigational- selective P2X3 receptor antagonist- to treat refractory or unexplained chronic cough

Click here ­to­ read full press release/ article 

 Ref: Merck | Image: Merck